Project Grant R21AI193783
Award Date 8/5/25
Completion Date 7/31/27
Dollars Obligated $159K
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
- The University of Pittsburgh was awarded a $547,537 Cooperative Agreement from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) on September 19, 2025. The purpose of this award is to investigate the mitigation of Acute Radiation Syndrome (ARS) by inhibiting the tyrosine kinase FGR, which is a master regulator of inflammation in the bone marrow following total body irradiation. Key objectives include: 1) demonstrating increased survival in FGR knockout mice...
- This Project Grant award from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) totaling $157,000.00 is supporting research to develop a new class of radiation mitigating agents as medical countermeasures for hematopoietic acute radiation syndrome (H-ARS). The principal investigators from the collaborative research partnership between Henry Ford Health and Michigan State University Health Sciences will examine the mitigating effects of the small molecule...
- This $431,750 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to examine the mitigating effects of the small molecule UTS-1401 on both hematopoietic acute radiation syndrome (H-ARS) and gastrointestinal acute radiation syndrome (GI-ARS) following whole body irradiation in Swiss mice. The researchers plan to administer UTS-1401 at various timepoints relative to radiation...
- This $167,500 Project Grant awarded by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) aims to develop the pentapeptide MSP68 as a novel and effective medical countermeasure to treat the gastrointestinal acute radiation syndrome (GI-ARS). The grant recipient, The Feinstein Institutes For Medical Research, will conduct research to demonstrate that MSP68 can mitigate GI-ARS by promoting the recovery of gut stem cells and reducing intestinal damage...
- This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $155,000 to the University of Kansas Medical Center Research Institute, Inc. (KUMCRI) to investigate the mitochondrial serine/threonine phosphatase PGAM5 as a potential target for mitigating gastrointestinal acute radiation syndrome (GI-ARS). The research aims to examine the role of PGAM5 in radiation-induced oxidative stress and modulation of Wnt/β-catenin...
- This Project Grant award of $153,000.00, provided by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310), focuses on investigating potential radiomitigating strategies for gastrointestinal acute radiation syndrome (GI-ARS). The research project has two novel approaches: 1) Evaluating the mitigating effects of dietary methionine restriction on GI-ARS following radiation exposure, and 2) Exploring a second approach outlined in Aim 2 (details not...
- This Project Grant award of $157,400 from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) is focused on developing an effective medical countermeasure against gastrointestinal acute radiation syndrome (GI-ARS). The primary objective is to establish the efficacy of Maroon Biotech's MP8800 copolymer in increasing 10-day and 30-day survival rates, as well as preserving gut barrier function, in a well-established rat model of GI-ARS. The research is...
- This federal Project Grant award of $185,831.00, provided by the National Cancer Institute (CFDA 93.395 Cancer Treatment Research), will support research to discover and develop allosteric inhibitors of the SRC-family kinases HCK and FGR for the treatment of acute myeloid leukemia (AML). The University of Pittsburgh will lead this exploratory 2-year project to identify small molecules that can selectively target and lock these kinases in an inactive conformation, with the goal of preventing...
- The U.S. Department of Health and Human Services, National Institutes of Health (NIH) awarded a $155,857 Project Grant under the Trans-NIH Research Support (CFDA 93.310) program to Signablok, Inc. in Massachusetts. The funding supports the development of a novel medical countermeasure to mitigate potentially lethal acute radiation syndrome (ARS). The project aims to create a well-tolerable and effective first-in-class therapeutic that can be administered at least 24 hours post-radiation exposure...
- This Project Grant award from the Department of Health and Human Services' National Institutes of Health (CFDA 93.310 - Trans-NIH Research Support) provides $149,008 to evaluate the use of PEG-BPEI as a potential mitigator against gastrointestinal acute radiation syndrome (GI-ARS). The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. will develop a murine model of partial body irradiation to study the effects of radiation on the GI tract while minimizing systemic...